A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Biogen has decided to close down its digital ... the company and its interactions with health systems, with three locations in Boston, Zurich, and Paris employing around 150 team members.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other oversold large cap stocks. The Fed recently reduced the funds rate by 50 basis points ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...